Sanofi Aventis announced results from its Phase 3 study of lixisenatide for the treatment of type 2 diabetes. The GetGoal-S, one of nine studies in the GetGoal Phase 3 clinical program, was a randomized, double-blind, placebo-controlled trial with a 24-week main treatment period. A total of 859 patients were randomized to receive either lixisenatide or placebo. Results showed that people in the lixisenatide group experienced a significant reduction in their HbA1c levels with a -0.74% difference vs. placebo (P<0.0001) at Week 24. It also improved patients’ 2-hour post-prandial glucose (P<0.0001), fasting plasma glucose levels (P<0.0001), and had significant decrease in body weight (P<0.0001) compared with those on placebo.

Lixisenatide is a glucagon-like peptide-1 agonist (GLP-1). 

For more information call (800) 981-2491 or visit